We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Why the Market Dipped But Amgen (AMGN) Gained Today
Read MoreHide Full Article
Amgen (AMGN - Free Report) closed at $303.17 in the latest trading session, marking a +0.82% move from the prior day. This move outpaced the S&P 500's daily loss of 0.34%. Elsewhere, the Dow gained 0.03%, while the tech-heavy Nasdaq lost 0.56%.
Shares of the world's largest biotech drugmaker witnessed a gain of 11.64% over the previous month, beating the performance of the Medical sector with its gain of 5.72% and the S&P 500's gain of 2.56%.
The upcoming earnings release of Amgen will be of great interest to investors. The company is forecasted to report an EPS of $4.69, showcasing a 14.67% upward movement from the corresponding quarter of the prior year. Simultaneously, our latest consensus estimate expects the revenue to be $8.13 billion, showing a 18.95% escalation compared to the year-ago quarter.
Investors should also pay attention to any latest changes in analyst estimates for Amgen. Such recent modifications usually signify the changing landscape of near-term business trends. As a result, upbeat changes in estimates indicate analysts' favorable outlook on the company's business health and profitability.
Based on our research, we believe these estimate revisions are directly related to near-team stock moves. To capitalize on this, we've crafted the Zacks Rank, a unique model that incorporates these estimate changes and offers a practical rating system.
The Zacks Rank system, stretching from #1 (Strong Buy) to #5 (Strong Sell), has a noteworthy track record of outperforming, validated by third-party audits, with stocks rated #1 producing an average annual return of +25% since the year 1988. Over the past month, the Zacks Consensus EPS estimate has moved 0.86% higher. Amgen is holding a Zacks Rank of #3 (Hold) right now.
In terms of valuation, Amgen is currently trading at a Forward P/E ratio of 15.17. This represents a discount compared to its industry's average Forward P/E of 22.33.
We can also see that AMGN currently has a PEG ratio of 2.7. This metric is used similarly to the famous P/E ratio, but the PEG ratio also takes into account the stock's expected earnings growth rate. As the market closed yesterday, the Medical - Biomedical and Genetics industry was having an average PEG ratio of 1.91.
The Medical - Biomedical and Genetics industry is part of the Medical sector. This group has a Zacks Industry Rank of 75, putting it in the top 30% of all 250+ industries.
The Zacks Industry Rank gauges the strength of our industry groups by measuring the average Zacks Rank of the individual stocks within the groups. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1.
Make sure to utilize Zacks.com to follow all of these stock-moving metrics, and more, in the coming trading sessions.
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Image: Bigstock
Why the Market Dipped But Amgen (AMGN) Gained Today
Amgen (AMGN - Free Report) closed at $303.17 in the latest trading session, marking a +0.82% move from the prior day. This move outpaced the S&P 500's daily loss of 0.34%. Elsewhere, the Dow gained 0.03%, while the tech-heavy Nasdaq lost 0.56%.
Shares of the world's largest biotech drugmaker witnessed a gain of 11.64% over the previous month, beating the performance of the Medical sector with its gain of 5.72% and the S&P 500's gain of 2.56%.
The upcoming earnings release of Amgen will be of great interest to investors. The company is forecasted to report an EPS of $4.69, showcasing a 14.67% upward movement from the corresponding quarter of the prior year. Simultaneously, our latest consensus estimate expects the revenue to be $8.13 billion, showing a 18.95% escalation compared to the year-ago quarter.
Investors should also pay attention to any latest changes in analyst estimates for Amgen. Such recent modifications usually signify the changing landscape of near-term business trends. As a result, upbeat changes in estimates indicate analysts' favorable outlook on the company's business health and profitability.
Based on our research, we believe these estimate revisions are directly related to near-team stock moves. To capitalize on this, we've crafted the Zacks Rank, a unique model that incorporates these estimate changes and offers a practical rating system.
The Zacks Rank system, stretching from #1 (Strong Buy) to #5 (Strong Sell), has a noteworthy track record of outperforming, validated by third-party audits, with stocks rated #1 producing an average annual return of +25% since the year 1988. Over the past month, the Zacks Consensus EPS estimate has moved 0.86% higher. Amgen is holding a Zacks Rank of #3 (Hold) right now.
In terms of valuation, Amgen is currently trading at a Forward P/E ratio of 15.17. This represents a discount compared to its industry's average Forward P/E of 22.33.
We can also see that AMGN currently has a PEG ratio of 2.7. This metric is used similarly to the famous P/E ratio, but the PEG ratio also takes into account the stock's expected earnings growth rate. As the market closed yesterday, the Medical - Biomedical and Genetics industry was having an average PEG ratio of 1.91.
The Medical - Biomedical and Genetics industry is part of the Medical sector. This group has a Zacks Industry Rank of 75, putting it in the top 30% of all 250+ industries.
The Zacks Industry Rank gauges the strength of our industry groups by measuring the average Zacks Rank of the individual stocks within the groups. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1.
Make sure to utilize Zacks.com to follow all of these stock-moving metrics, and more, in the coming trading sessions.